Genomics & Omics Analysis - software & AI news

Daily news on software, AI, and companies shaping genomics & omics analysis.

Showing 125 results
A tissue sample on a laboratory countertop with a notebook in the background.

Jun 6, 2026

Is Tempus AI’s (TEM) New Oncology Tools Quietly Redefining Its Precision Medicine Moat?

Tempus AI is making significant strides in oncology with recent advancements that include FDA approval for its xT CDx tumor-only sequencing platform and the upcoming launch of its xH whole-genome test. These innovations are part of a broader strategy to integrate AI into precision medicine, aiming to create a comprehensive infrastructure for diagnostics and drug development.With the FDA's endorsement of the xT CDx platform, Tempus AI is poised to enhance its market position by potentially conver
A tumor sample on a microscope slide in a dimly lit lab

Jun 4, 2026

SOPHiA GENETICS Signs Strategic Collaboration MOU with Leading Global Cancer Center

SOPHiA GENETICS has announced a strategic collaboration with Memorial Sloan Kettering Cancer Center (MSK) to establish a precision medicine hub aimed at advancing precision oncology.The Memorandum of Understanding (MOU) between SOPHiA GENETICS and MSK seeks to leverage the strengths of both organizations. SOPHiA’s DDM™ platform has analyzed over 2.5 million cases since its inception, while MSK has sequenced more than 150,000 tumor samples, creating a rich dataset that integrates clinical outcome
A stack of research papers in a dimly lit lab, symbolizing human genetics data.

Jun 4, 2026

Genomics Launches Mystra AI Platform to Accelerate Drug Target Discovery Using Human Genetics Data

Genomics has introduced the Mystra AI platform, aiming to enhance drug target discovery by leveraging extensive human genetics data.The London-based techbio company has developed Mystra AI, a conversational AI tool designed to facilitate drug target identification and validation. This platform is already in use by prominent pharmaceutical companies and biotech startups, addressing the high failure rates in drug development, where approximately 95% of candidates fail in clinical trials. Genomics
A DNA sequencing sample on a lab bench with a pipette

Jun 3, 2026

AI tool simplifies and scales complete genome assembly, supporting advances in diagnostics and precision medicine

An innovative AI tool called HERRO has been developed to enhance the accuracy and efficiency of complete genome assemblies, potentially revolutionizing diagnostics and precision medicine.HERRO, created by an international team led by the A*STAR Genome Institute of Singapore, utilizes deep learning to rectify errors in nanopore sequencing reads from Oxford Nanopore Technologies (ONT). This technology is particularly valuable for reading long DNA sequences, which are essential for analyzing comple
Minimalist illustration of DNA and graph line representing genomics data

Jun 3, 2026

M42, Arcera team up to boost medicine and biotech growth in Abu Dhabi

A new collaboration between M42 and Arcera aims to enhance the life sciences landscape in Abu Dhabi, focusing on a comprehensive ecosystem for clinical development and innovative therapies.The partnership is set to leverage the strengths of both organizations, with M42 bringing its expertise in healthcare and artificial intelligence, while Arcera contributes its experience in drug development and market access. Together, they will utilize genomics data to investigate the prevalence of selected g
A minimalist representation of a blood droplet and an immune cell silhouette.

Jun 2, 2026

London biotech raises $53M to decode the immune system using a single blood sample

IMU Biosciences has successfully raised over $53 million in an extended Series A funding round, aimed at revolutionizing immune system analysis through advanced technology.The London-based biotech firm, co-led by IQ Capital and Molten Ventures, has developed the largest immune dataset in the world, encompassing over 25,000 individuals and generating more than 100 million immune data points from a single blood sample. This innovative approach addresses a significant gap in precision medicine, whe
DNA sample on a laboratory bench

Jun 2, 2026

Europe’s Next-Generation Sequencing Market Is Entering a New Era of Genomic Innovation

Europe is on the brink of a genomic revolution, driven by advancements in Next-Generation Sequencing (NGS) technologies that are reshaping healthcare toward personalized medicine.The integration of NGS into healthcare systems across Europe is transforming diagnostics and treatment strategies. With significant investments from governments, academic institutions, and biotechnology firms, the European NGS market is projected to surge from approximately $2.43 billion in 2025 to around $13.94 billion
A mass spectrometer in a research lab

May 31, 2026

Is Thermo Fisher (TMO) Turning AI-Enabled Orbitraps Into a Durable Edge in Life Sciences Tools?

Thermo Fisher Scientific recently unveiled its advanced Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers at the ASMS Conference, showcasing significant advancements in sensitivity, speed, and compound detection for complex research applications in multiomics and pharmaceuticals.The integration of these new Orbitrap systems with Thermo Fisher's Olink proteomics and AI-driven software solutions aims to streamline the transition from discovery-scale data to regulatory-ready analysis a
A blood test vial representing AI-driven diagnostics in women's health

May 28, 2026

AWHL: AI-driven diagnostics improve detection and reduce surgeries in women's health

AI technologies are significantly enhancing diagnostic capabilities in women's health, particularly for conditions like ovarian cancer and endometriosis.Recent advancements in AI-driven, multi-omic diagnostics are poised to benefit over 10 million women by providing innovative blood tests that improve the accuracy of detection for these conditions. This technological shift not only enhances patient care but also aims to minimize unnecessary surgical procedures, which can carry various risks and
Flat illustration of microRNA and protein biomarkers

May 27, 2026

Aspira Women’s Health and Cleveland Clinic Expand Collaboration on AI-Powered Diagnostics for Ovarian Cancer and Endometriosis

Aspira Women’s Health has partnered with Cleveland Clinic to enhance AI-driven diagnostics aimed at ovarian cancer and endometriosis. This collaboration seeks to leverage advanced biomarker discovery and analytical models to improve women’s health diagnostics.The partnership will focus on developing non-invasive tests, building on Aspira's existing OvaSuite, which helps assess ovarian cancer risk for over a million American women annually. Plans include expanding their diagnostic offerings by in
Minimalist illustration of a heart valve and blood vessel

May 27, 2026

Cardio Diagnostics Holdings, Inc. to Showcase Precision Cardiovascular Solutions at Four National Benefits Conferences in June

Cardio Diagnostics Holdings, Inc. is set to showcase its innovative cardiovascular solutions at four key national benefits conferences this June, addressing the critical issue of cardiovascular disease (CVD), a leading cost driver for health plans.The company will present its advanced blood tests, Epi+Gen CHD™ and PrecisionCHD™, which utilize a combination of epigenetics, genetics, and artificial intelligence to identify individuals at risk for severe cardiac events. These tests aim to enhance p
A minimalist illustration of a lymph node and a cancer cell in a dark palette.

May 26, 2026

Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing

Caris Life Sciences has launched the "Behind the Diagnosis" campaign to highlight the transformative impact of its genomic testing on patient care.The inaugural story features Erika Rios, whose initial diagnosis of stage 4 metastatic triple-negative breast cancer was corrected through Caris GPSai, an AI-driven tissue-of-origin model. This innovative tool revealed her actual condition as Hodgkin lymphoma, a significantly more treatable cancer. The case underscores the importance of accurate molec